Vitruvian Partners Increases Stake in Civitatis
Vitruvian Partners has purchased a further ownership stake in Civitatis, the leading curated online marketplace for guided tours and activities for Spanish and Portuguese speaking consumers, investing an additional USD 50m. Civitatis continues to be led by the founder and CEO Alberto Gutiérrez, who established the company in 2008.
Civitatis is a rare example of a company that has been cashflow positive from day one, built by its founder without any external capital. The Company remains on track to be a future Spanish unicorn, as a curated marketplace for the large and growing tours and activities category, underpinned by a rapid digitalization tailwind. Founder and CEO Alberto Gutiérrez said, “Our growth and profitability have been fuelled by a combination of highly effective sales channels, well-invested technology platform, and a customer-centric approach, providing the activities and tours in our customers’ own preferred language. Our customers appreciate our expertly curated catalogues of activities across the world, as well as the easy booking and, of course, the outstanding experience that they have with us. With the support of Vitruvian, we are continuing to expand our offerings and meet the demands of our rapidly growing customer base.”
The company, headquartered in Madrid, offers 90,000 activities across 160 countries, with over 10 million customers in 2023. Vitruvian Partner, Sophie Bower-Straziota, said, “Under Alberto’s strong leadership Civitatis has grown at an exceptional rate, 50% each year, whilst maintaining continuous and strong profitability. The market potential is large and growing, with c.750 million Spanish and Portuguese speakers worldwide. We were delighted to have the opportunity to increase our shareholding and provide additional support for the company to continue its impressive expansion.”
Over the coming years Civitatis will continue to cement its position as the premier brand for tours and activities for customers across Spain and Latin America, with a particular focus on Mexico, Brazil, and Argentina, where it has already held the top position in sales for years. The investment is the sale of secondary shares, as the company has no need for primary capital, having been profitable since inception.
About Civitatis
Civitatis is the leading curated marketplace for tours and activities in Spanish with more than 90,000 activities in 4,000 destinations across 160 countries.
About Vitruvian
Vitruvian Partners is an international growth-focused investor with offices across London, Madrid, Miami, Stockholm, Munich, Luxembourg, San Francisco, Singapore, Mumbai and Shanghai. Vitruvian focuses on dynamic situations characterized by rapid growth and change across asset-light industries. Vitruvian has c.$20bn of active funds. The funds have backed many global leaders within areas of travel and experiences technology, including Skyscanner, Fever, Sykes, Travel Counsellors, OAG and Jac Travel; as well as other technology leaders such as Just Eat, Wise, Darktrace, CRF Health, Snow Software and Bitdefender.
Further information can be found at www.vitruvianpartners.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240626170775/en/
Contacts
Siobhan Loftus at Vitruvian Partners
Siobhan.Loftus@vitruvianpartners.com
Óscar Fernández
(Head of Communications)
ofernandez@civitatis.com
+34 609 488 694
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SLB OneSubsea awarded subsea boosting contract by Petrobras for the Búzios field, offshore Brazil12.12.2024 14:22:00 CET | Press Release
Global energy technology company SLB (NYSE: SLB) today announced a contract award by Petrobras, following a competitive tender, to its OneSubsea™ joint venture for two subsea raw seawater injection (RWI) systems to increase recovery from the prolific Búzios field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212795762/en/ Under the contract, SLB OneSubsea will provide two complete subsea RWI systems to support Petrobras’ FPSOs P-74 and P-75, and they will each consist of a subsea seawater injection pump, umbilical system and topside variable speed drive. (Photo: Business Wire) The subsea RWI systems will help to increase the production of floating production storage and offloading (FPSO) vessels, which are currently bottlenecked in their water injection capacities. Once operational, the RWI systems will reduce greenhouse gas (GHG) emissions per barrel of oil as they are a more efficient means of reservoir pressurization
EnerSys Wins Prestigious German ESG Transparency Award12.12.2024 14:15:00 CET | Press Release
EnerSys(NYSE: ENS), the global leader in stored energy solutions for industrial applications, is proud to announce it has been honored with the German ESG Transparency Award. This distinguished accolade recognizes organizations that demonstrate exemplary transparency and accountability in their environmental, social, and governance (ESG) initiatives. The ESG Transparency Award, presented annually in Germany, highlights the importance of clear and comprehensive ESG reporting as a cornerstone of corporate responsibility. This recognition underscores EnerSys’ steadfast commitment to sustainable practices and its leadership in advancing ESG standards within the industrial energy sector. “Receiving the ESG Transparency Award is a tremendous honor and a testament to EnerSys' dedication to transparency and continuous improvement in our global sustainability journey. At EnerSys, we believe in ‘Powering the Future, Everywhere for Everyone,’ and this recognition underscores our commitment to con
Parse Biosciences Launches Evercode Mouse BCR to Support Antibody Engineering and Development for Drug Discovery Applications12.12.2024 14:15:00 CET | Press Release
Parse Biosciences, a leader in scalable single cell sequencing solutions, today announced the expansion of its Evercode BCR™ product line to enable applications in mice. The new kits enable researchers to profile the mouse BCR repertoire alongside whole transcriptome data for millions of cells in a single experiment, offering unmatched scale and efficiency for antibody discovery. The Evercode BCR platform is designed to streamline workflows for antibody research, allowing scientists to identify individual antibody-producing cells and their clonally-related groups that generate specific antibodies of interest. Unique features, such as sample fixation capabilities, allow researchers to preserve cells and samples from mice for up to six months, thereby reducing the need to harvest additional mice and maximizing the yield per discovery campaign. Further, the technology eliminates the requirement for costly equipment, making advanced single cell analysis accessible with standard laboratory
1NCE Trains Software Innovators on Simplifying IoT Solutions12.12.2024 14:15:00 CET | Press Release
1NCE, one of the fastest-growing companies in the Internet of Things (IoT), announces the launch of its Certified Integrators Program (CIP). The program empowers external software developers to integrate seamlessly with 1NCE’s IoT platform, simplifying the development of connected solutions and enhancing customer success. The program marks a new step for 1NCE’s Partner Initiative, which counts more than 80 companies supporting 1NCE and its 23,000 customers managing 30 million endpoints worldwide. By offering hands-on training and certification, 1NCE equips integrators with tools to deliver streamlined, cost-effective IoT implementations for businesses across industries. A key aspect of 1NCE's strategy is its dedication to providing open access, enabling top software developers to collaboratively build connected products on the 1NCE platform. The CIP starts with a comprehensive education program for partners to become certified experts in 1NCE’s IoT platform, then continues with teachin
Tanner Pharma Expands Global Access to Botensilimab and Balstilimab Through Partnership With Agenus12.12.2024 14:00:00 CET | Press Release
Tanner Pharma, a global provider of specialty medicine access solutions, today announced a collaboration with Agenus, a leading immuno-oncology company, to provide expanded access to botensilimab (BOT) and balstilimab (BAL). Through a Named Patient Program (NPP), this initiative offers patients with microsatellite stable colorectal cancer (MSS CRC) and other advanced solid tumors the opportunity to access BOT/BAL based on supporting clinical evidence and medical need. Tanner Pharma will manage access to BOT/BAL for patients in geographies that allow named patient access to investigational medicines. The NPP ensures that patients, in consultation with their physicians, can access BOT/BAL even before regulatory approval, adhering to all ethical and compliance standards. BOT and BAL are investigational immunotherapies designed to target challenging cancers, including MSS CRC and other tumors historically resistant to immune-based treatments. Clinical outcomes have demonstrated complete pa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom